Muna, GSK partner to develop targets for Alzheimer's treatments
Dec 6, 2024 · The research collaboration will leverage Muna’s MiND-MAP platform, which analyzes analyze post-mortem brain samples from people with Alzheimer’s and compares them with the brains of healthy individuals, centenarians with and without cognitive impairment, and people without cognitive decline despite age or exposure to risk factors.. This approach is designed to help uncover the genetic and ...
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
Sep 26, 2024 · The board’s findings were announced by therapy developer Cassava Sciences, which said in a press release that the company expects to share data from one clinical trial later this year, and from the other by the middle of next year.. The two trials, dubbed RETHINK-ALZ (NCT04994483) and REFOCUS-ALZ (NCT05026177), have collectively enrolled 1,929 people with mild to moderate Alzheimer’s.
Light the world teal for November’s Alzheimer’s Awareness Month
Oct 31, 2024 · To help advocates get the word out, the AFA has prepared resources including an Alzheimer’s fact sheet and tips for healthy aging.The foundation also is offering images that can be used as cover photos to tell the world about going teal for Alzheimer’s awareness and loving someone with Alzheimer’s.. Alzheimer’s disease is a neurological condition marked by problems with memory and ...
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study
Nov 8, 2024 · The modified dosing regimen reduced ARIA-E the most in patients with two copies of the ApoE4 gene variant, which is known to have a high genetic risk for Alzheimer’s. With the modification, 19% of these patients experienced ARIA-E compared with 57% on the standard dosing regimen, lowering their relative risk by 67%, according to Eli Lilly.
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
Jul 11, 2024 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
For Alzheimer's, Dementia Patients, a Water-filled Jelly Drop for...
May 24, 2022 · “In the care home, I really wanted Jelly Drops to tackle dehydration and also to be really fun and engaging and sort of a social tool in the care home as well,” Hornby said in a video interview with Alzheimer’s News Today.. Hornby created the forerunner to Jelly Drops for his master’s graduation project at Imperial College London and …
Alzamend Neuro sets trial dosage for AL001 lithium therapy
Oct 24, 2024 · Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials.
Alzheimer’s blood test gets FDA breakthrough device designation
Mar 14, 2024 · The test, Simoa p-Tau 217, has the potential to help doctors diagnose Alzheimer’s in people with cognitive decline before the patients show outward signs of the disease. Alzheimer’s begins with the buildup of proteins, which can be detected via imaging tests before symptoms such as memory loss and disorientation appear. “Early detection is crucial in shaping effective care strategies and ...
Alzheimer's News Today Home | Alzheimer's News Today
Dec 9, 2024 · Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer’s. Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E, or amyloid-related imaging abnormalities associated with brain swelling, among adults with the neurodegenerative ...